The Clinical Efficacy Of DC-CIK-CTL Cell Immunotherapy For Non-small Cell Lung Cancer (NSCLC)

Objective: The aim of this study is to evaluate the clinical efficacy of the DC-CIK-CTL cellular immune treatment in advanced non-small cell lung cancer(non-small cell lung cancer,NSCLC).The Dendritic Cells(DC)and Cytokine induced killer cells(CIK)were induced from the separated Peripheral blood mononuclear cells(PBMC),and then mixed to prepare CTL cells.Biological immunotherapy plays an important role in improving the immune surveillance function of the body.what’s more,even exponentially killing of malignant tumor after the treatment of traditional radiation and chemotherapy,the tiny residual tumor cells are still need to be managed by mobilizing the body’s immune function to achieve complete control.By this study,we hope to find more kinds and more effective methods for the treatment of advanced NSCLC.Methods: 120 patients with advanced NSCLC were retrospectively analyzed,who were hospitalized in our hospital from May 2009 through May 2016.The whole sample pool were divided into two groups,observation group and control group.In the observation group,60 patients were performed with DC-CIK-CTL cellular biological treatment combined with pre-conditioning chemotherapy.In the control group,anther 60 cases of lung cancer patients were performed with regular radiotherapy and chemotherapy.The differences of some indicators were compared between the two groups including the disease control rate,the improvement of quality of life and the adverse reactions,and so on.Results: The disease control rate has a significant difference between the two groups as 85% and 76.6%,respectively(P<0.05).In terms of quality of life,the total improvement rate of Karnofsky was 86.6% compared with that of the pure chemotherapy group(75%),a statistically significant difference(P<0.05)was observed.The NK cells and T-cell subgroups of the treatment group had significant changes before and after treatment.Serum tumor markers CA125,CEA,CA 19-9 were reduced in different degrees in the group of observation group.The test results of Liver and kidney function and blood routine were within normal range.In the observation group,9 patients developed fever symptoms after infusion of DC-CIK-CTL cells.One patient showed chest distress,and 3 patients showed signs of fatigue.Conclusions:1.DC-CIK-CTL cells can promote the improvement of patients’ disease control rate and improve the quality of life for patients with advanced NSCLC。DC-CIK-CTL cells increase the proportion of CD3,CD4 and NK cells in peripheral blood of patients with advanced NSCLC,and thus contribute to the enhancement of anti-tumor immune function of such patients.2.No obvious adverse reactions occurred during the treatment of DC-CIK-CTL cells。The effect of DC-CIK-CTL is not closely related to the pathological type of NSCLC.